ACR Convergence 2026 has ended. This guide stays up as the record of who was there. See upcoming conferences

Johnson & Johnson at ACR Convergence 2026

Nov 6–11, 2026 Orlando, FL ~15k attendees Website

Johnson & Johnson brings 12 presentations to ACR Convergence 2026 in Orlando, and exhibits at Booth 3228. Its program centres on psoriatic arthritis, with guselkumab trial results, treatment persistence and a discussion of axial involvement. It also covers Sjögren's disease, including nipocalimab, healthcare use and mortality in Swedish population studies.

OrganizationACR Convergence 2026 Attendance
Johnson & Johnson
New Brunswick, NJ
Pharmaceutical companies
A healthcare company with pharmaceutical and medical-device businesses.
Booth
Exhibiting at Booth 3228
Sun, Nov 810:00am–5:00pmMon, Nov 910:00am–5:00pmTue, Nov 1010:00am–2:30pm
Industry
Sun Nov 8
12:30pm–1:15pm
Managing Active PsA Across Multiple Key Domains: A Clinical Discussion on Axial Involvement
Innovation Theater A
Spondyloarthritis and PsA · with Swedish Medical Center/Providence St. Joseph Health, University of Toronto

Explore the full ACR Convergence 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Orlando. Leave your work email and we’ll be in touch.

Privacy

Download the full ACR Convergence 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Johnson & Johnson

Tell us what you sell and we’ll find the people at Johnson & Johnson most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the American College of Rheumatology (ACR). Organization details are derived from the ACR’s published program and exhibitor floor plan, and each organization’s own website. Submit a correction